Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $83.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 1.32; Below-average business quality.
Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for... Read more
Sell if holding. Engine safety override at $83.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 1.32; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Score 4.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Spyre Therapeutics, Inc.
About Spyre Therapeutics, Inc.
Spyre Therapeutics advanced six investigational agents—SPY001 (anti-α4β7), SPY002 (anti-TL1A), SPY003 (anti-IL-23), and three pairwise fixed-dose combinations—into the SKYLINE Phase 2 platform trial in May 2025, targeting moderately to severely active ulcerative colitis, with Part A induction data expected in Q2 2026. The company held $756.5 million in cash, cash equivalents, and marketable securities at December 31, 2025, and reported a net loss of $155.2 million for the year, employing 102 full-time staff.
Spyre has no approved products and generates no revenue from sales; operations are funded through equity and debt financings. SPY001 demonstrated a pharmacokinetic profile supporting potential quarterly or twice-annual maintenance dosing based on Phase 1 data through eight months of follow-up; SPY002 and SPY072 showed complete suppression of free TL1A through up to 20-24 weeks at a single 100 mg dose. SPY003 data presented in February 2026 demonstrated comparable PK differentiation supporting quarterly or twice-annual dosing. All nonclinical and clinical manufacturing is outsourced to third parties, with WuXi Biologics supplying GMP manufacturing for the SPY001, SPY002, and SPY003 programs under a master services agreement running to October 2029. The Fiscal Year 2026 National Defense Authorization Act, signed December 18, 2025, includes BIOSECURE Act provisions that could limit engagement with certain foreign biotechnology manufacturers, prompting Spyre to accelerate supply chain redundancy outside China.
Show full overview
Spyre's near-term value is concentrated in two binary readout windows: SKYLINE Part A induction data for SPY001, SPY002, and SPY003 monotherapies expected in Q2 2026, and SKYWAY topline proof-of-concept data for SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis expected in Q4 2026. The 10-K states the company is substantially dependent on the success of the SPY001, SPY002, SPY072 and SPY003 programs. Part B of SKYLINE—testing pairwise combinations including SPY120, SPY130, and SPY230—is not expected to yield induction data until 2027, leaving the clinical calendar heavily concentrated in the 2026 readout windows.
See also: Healthcare · Biotechnology
From Spyre Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Spyre Therapeutics, Inc.
Latest news
- NEWS Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcer — benzinga Jun 15, 2026 positive
- NEWS CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday — benzinga Jun 4, 2026 neutral
- NEWS Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115 — benzinga Jun 4, 2026 positive
- NEWS Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday — benzinga Jun 3, 2026 positive
- NEWS Spyre Therapeutics Completes Enrollment For All Sub-Studies In SKYWAY Basket Trial Of SPY072 In Rheumatic Diseases — benzinga Jun 3, 2026 positive
Generated 2026-06-17T08:36:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierWuXi Biologics10-K Item 1: 'The WuXi Biologics MSA governs certain development activities and Good Manufacturing Practice (“GMP”) manufacturing and testing for the SPY001, SPY002, and SPY003 programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $83.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 1.32; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Prior stop was $77.29. Score 4.7/10, moderate confidence.
Take-profit target: $86.46 (+4.0% upside). Prior stop was $77.29. Stop-loss: $77.29.
Concentration risk — Supplier: WuXi Biologics; Quality below floor (1.2 < 4.0).
Spyre Therapeutics, Inc. trades at a P/E of N/A (forward -26.4). TrendMatrix value score: 5.0/10. Verdict: Sell.
23 analysts cover SYRE with a consensus score of 4.5/5. Average price target: $96.
What does Spyre Therapeutics, Inc. do?Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and...
Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for RA/PsA/axSpA). As of December 31, 2025, Spyre had $756.5 million in cash and no approved products generating revenue.